Bruker Corporation

What they do

Bruker operates four reportable segments: BSI BioSpin (magnetic resonance, preclinical imaging, biopharma, and services), BSI CALID (chemicals, applied markets, life science, in vitro diagnostics, detection), BSI NANO (nanotechnology and metrology), and BEST (energy and superconductor technologies). Products include NMR and EPR systems, mass spectrometry, chromatography, X-ray, microscopy, and molecular spectroscopy. The company serves academic, government, pharmaceutical, biotech, industrial, and clinical customers, with headquarters in Billerica, Massachusetts.

Revenue drivers

• BSI BioSpin — Core segment offering NMR, EPR, preclinical imaging, and biopharma solutions; largest share of scientific instruments revenue, driven by academic and government research customers, plus recurring service and lifecycle support.
• BSI CALID — Includes mass spectrometry, chromatography, and molecular spectroscopy; serves life science, applied markets, in vitro diagnostics, and detection; contributes to broad instrument portfolio.
• BSI NANO — Focuses on microscopy and metrology for nanotechnology and semiconductor applications; recent strong bookings in semiconductor tools noted by management.
• BEST (Bruker Energy & Supercon Technologies) — Generates revenue from energy research and superconductor technologies; Q2-26 revenue of $74.2 million, up 11.9% year-over-year, with organic growth of 8.9%.

Recent performance

For Q2-26, revenue was $838.5 million, up 5.2% year-over-year, with organic growth of 2.8% (3.4% excluding tariff refunds). GAAP diluted loss per share was $(0.41), reflecting non-cash goodwill impairment charges of $134.9 million; non-GAAP diluted EPS was $0.49. Segments: BSI revenue $767.3 million (+4.7% yoy, organic +2.3%), BEST revenue $74.2 million (+11.9% yoy, organic +8.9%). For the first half of 2026, revenue was $1.7 billion, up 3.9% yoy, but organic revenue decreased 0.8%; GAAP operating loss was $(55.1) million, while non-GAAP operating income was $202.7 million. In FY2025, annual revenue was $3.44 billion with net income of $-8.3 million.

Strategy

Management is focused on returning to organic growth and improving profitability, with emphasis on cost reduction and margin expansion. In Q2-26, BSI bookings grew 10% organically year-over-year, with book-to-bill above 1.0x, driven by semiconductor tools, energy research, and biopharma markets. The company is also gaining confidence in a gradual market recovery and expects significant organic margin expansion in both 2026 and 2027. Prior initiatives include expanding into high-potential markets and driving recurring revenue through aftermarket services.

Risks

• US academic funding cuts — Reduced NIH, NSF, and DOE funding has materially adversely affected U.S. academic demand, which softened in Q2-26.
• Supply chain constraints — Shortages of semiconductor chips, components, and raw materials like copper could cause manufacturing inefficiencies and higher costs.
• Tariff and trade policy uncertainty — New U.S. and reciprocal tariffs have had a material adverse effect on results, and potential future changes add uncertainty.
• Geopolitical tensions — Conflicts in Ukraine, Middle East, China, Taiwan, and elsewhere could disrupt supply chains, customer demand, and global operations.

Outlook

For FY2026, management updated guidance for currency and tax only, expecting revenue of $3.54 to $3.57 billion (3% to 4% reported yoy growth, organic growth of 1% to 2%, M&A growth of ~1.5%, CER growth of 2.5% to 3.5%). Non-GAAP EPS is expected to be $2.10 to $2.15, up 15% to 17% yoy. Management also expects significant organic margin expansion and non-GAAP EPS growth in 2027, citing a gradual market recovery and strong bookings in certain verticals.